Collaboration - January 8, 2016
Bavarian Nordic collaborates with Janssen
Janssen Pharmaceuticals has entered into a collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen’s own AdVac technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of HPV chronic infections which can lead to cancer. Under this agreement, Janssen will conduct all clinical development […]
Agreement - January 15, 2014
Orion Corporation signs license agreement with Janssen Pharmaceuticals
Orion Corporation has entered into a license agreement with Janssen Pharmaceuticals for the development and commercialization of Orion’s novel, investigational alpha-2c adrenoceptor antagonists for the symptoms of Alzheimer’s disease, including a clinical phase compound ORM-12741. According to the agreement, Orion will receive an upfront payment of USD 31 million and is eligible to receive milestone […]